Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.

Employees

339

Sector

Pharmaceuticals

Calendar

01:38am Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-11-10	₹482.25	+2.00%	6,699
26-11-09	₹472.80	+2.00%	505
26-11-08	₹463.55	+1.99%	83
26-11-06	₹454.50	+1.55%	10,171
26-11-05	₹447.55	+1.99%	1,386

End-of-day quote NSE India S.E.

More quotes

End-of-day quote NSE India S.E. 2026-11-11			5-day change	1st Jan Change
482.25 ^INR	+2.00%		+12.10%	+219.96%

01:21pm	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

Market Cap	11.41B 122M 110M 101M 91.56M 173M 178M 1.21B 484M 6.11B 456M 447M 19.44B	P/E 2025	42.6x	P/E 2026	23.3x
Enterprise Value	11.76B 125M 113M 104M 94.4M 179M 183M 1.25B 499M 6.3B 471M 461M 20.05B	EV / Sales 2025	1.38x	EV / Sales 2026	1.95x
Free-Float	10.3%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
NSE India S.E.	BAFNAPH	End-of-day quote
Bombay S.E.	BAFNAPH	Delayed

01:21pm	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI
05-29	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
25-09-19	Bafna Pharmaceuticals Limited Appoints Navin Kumar as Non-Executive, Independent Director	CI
25-08-12	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-12	Bafna Pharmaceuticals Limited Approves Reconstitution of Nomination & Remuneration Committee, Effective August 12, 2025	CI
25-06-24	Bafna Pharmaceuticals Limited Announces Board and Committee Changes, Effective from June 24, 2025	CI
25-05-26	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	CI
25-04-01	Bafna Pharmaceuticals Limited Announces Resignation of Krishna Yeachuri as Independent Director and Cessation as Chairman of Nomination & Remuneration Committee, Effective March 31, 2025	CI
25-02-06	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
24-11-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI

Bafna Pharmaceuticals Limited Stock

Stocks

BAFNAPH

INE878I01022

Pharmaceuticals

Valuation: Bafna Pharmaceuticals Limited

Chart: Bafna Pharmaceuticals Limited

Latest news: Bafna Pharmaceuticals Limited

Quotes and Performance

Price Extremes

Managers and Directors: Bafna Pharmaceuticals Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+2.00%
1 week	+12.10%
Current month	+7.67%
1 month	+15.37%
3 months	+72.66%
6 months	+265.34%
Current year	+219.96%

1 week	447.55	482.25
1 month	426.35	482.25
Current year	94.77	482.25
1 year	94.77	482.25
3 years	69	482.25
5 years	69	482.25
10 years	4.4	482.25

Manager	Title	Age	Since
Bansilal Mahaveer C. Bafna CEO	Chief Executive Officer	65	1980-12-31
Melagiri Sridhar DFI	Director of Finance/CFO	-	-
A. Mohanachandran CMP	Compliance Officer	-	2024-05-28

Director	Title	Age	Since
Hemalatha Shanmugam BRD	Director/Board Member	51	2020-09-09
Akilapriya C. Raju BRD	Director/Board Member	-	2020-09-09
Chitra Ravichandran CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAFNA PHARMACEUTICALS LIMITED	+2.00%	+12.10%	+163.12%	+488.47%	119M
ELI LILLY AND COMPANY	+0.35%	+1.36%	+45.38%	+134.58%	1,276B
JOHNSON & JOHNSON	-0.13%	+1.48%	+44.67%	+89.94%	676B
ABBVIE INC.	+0.37%	+0.05%	+31.00%	+112.77%	519B
ROCHE HOLDING AG	+0.02%	+2.79%	+44.10%	+69.76%	388B
MERCK & CO., INC.	-0.59%	-2.11%	+61.83%	+43.63%	365B
NOVARTIS AG	-1.29%	+0.94%	+29.88%	+58.29%	307B
ASTRAZENECA PLC	+0.09%	+0.99%	+5.87%	+37.72%	287B
AMGEN INC.	+0.62%	-2.17%	+38.31%	+75.53%	252B
GILEAD SCIENCES, INC.	-0.67%	-2.72%	+38.49%	+126.52%	212B
Average	+0.20%	+2.88%	+50.26%	+123.72%	428B
Weighted average by Cap.	+0.08%	+2.51%	+40.30%	+95.43%

	2025	2026
Net sales	1.46B 15.55M 14.02M 12.95M 11.71M 22.15M 22.69M 155M 61.86M 781M 58.36M 57.12M 2.49B	1.51B 16.06M 14.47M 13.37M 12.09M 22.87M 23.43M 160M 63.87M 807M 60.27M 58.99M 2.57B
Net income	41.52M 443K 399K 369K 333K 631K 646K 4.42M 1.76M 22.24M 1.66M 1.63M 70.77M	111M 1.18M 1.07M 985K 891K 1.69M 1.73M 11.81M 4.71M 59.45M 4.44M 4.35M 189M
Net Debt	248M 2.64M 2.38M 2.2M 1.99M 3.76M 3.85M 26.35M 10.5M 133M 9.91M 9.7M 422M	354M 3.78M 3.4M 3.14M 2.84M 5.38M 5.51M 37.68M 15.02M 190M 14.17M 13.87M 603M